[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054209":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":35,"responsibleParty":155,"collaborators":30,"id":157,"slug":30,"hasResults":158,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":158,"sex":164,"minAge":165,"maxAge":30,"enrollmentInfo":166,"targetDuration":30,"studyType":169,"phases":170,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":38,"whyStopped":30,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":195},{"fullName":5,"class":6},"Exelixis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Zanzalintinib","EXPERIMENTAL","Participants will receive zanzalintinib once daily (QD).",[13],"Drug: Zanzalintinib",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Administered as specified in the treatment arm.",[9],[20],"XL092",[22],{"name":23,"affiliation":5,"role":24},"Study Director","STUDY_DIRECTOR",[26,32],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Exelixis Clinical Trials","CONTACT","1-888-EXELIXIS (888-393-5494)",null,"druginfo@exelixis.com",{"name":33,"role":28,"phone":34,"phoneExt":30,"email":30},"Backup or International","650-837-7400",[36,49,59,69,78,88,97,106,116,126,135,145],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":30},"University of Alabama","RECRUITING","Birmingham","Alabama","35294","United States",{"type":44,"coordinates":45},"Point",[46,47],-86.80249,33.52066,{"lat":47,"lon":46},{"facility":50,"status":38,"city":51,"state":52,"zip":53,"country":42,"cosmosGeoPoint":54,"geoPoint":58,"contacts":30},"Mayo Clinic_Arizona","Phoenix","Arizona","85054",{"type":44,"coordinates":55},[56,57],-112.07404,33.44838,{"lat":57,"lon":56},{"facility":60,"status":38,"city":61,"state":62,"zip":63,"country":42,"cosmosGeoPoint":64,"geoPoint":68,"contacts":30},"Mayo Clinic_Jacksonville","Jacksonville","Florida","32224",{"type":44,"coordinates":65},[66,67],-81.65565,30.33218,{"lat":67,"lon":66},{"facility":70,"status":38,"city":71,"state":62,"zip":72,"country":42,"cosmosGeoPoint":73,"geoPoint":77,"contacts":30},"Baptist Health Miami Cancer Institute","Miami","33176",{"type":44,"coordinates":74},[75,76],-80.19366,25.77427,{"lat":76,"lon":75},{"facility":79,"status":38,"city":80,"state":81,"zip":82,"country":42,"cosmosGeoPoint":83,"geoPoint":87,"contacts":30},"Washington University School of Medicine","Bay Saint Louis","Mississippi","63110",{"type":44,"coordinates":84},[85,86],-89.33005,30.30881,{"lat":86,"lon":85},{"facility":89,"status":38,"city":90,"state":90,"zip":91,"country":42,"cosmosGeoPoint":92,"geoPoint":96,"contacts":30},"Memorial Sloan-Kettering Cancer Center","New York","10065",{"type":44,"coordinates":93},[94,95],-74.00597,40.71427,{"lat":95,"lon":94},{"facility":98,"status":38,"city":99,"state":90,"zip":100,"country":42,"cosmosGeoPoint":101,"geoPoint":105,"contacts":30},"Mayo Clinic_Rochester","Rochester","55905",{"type":44,"coordinates":102},[103,104],-77.61556,43.15478,{"lat":104,"lon":103},{"facility":107,"status":38,"city":108,"state":109,"zip":110,"country":42,"cosmosGeoPoint":111,"geoPoint":115,"contacts":30},"Duke University","Durham","North Carolina","27710",{"type":44,"coordinates":112},[113,114],-78.89862,35.99403,{"lat":114,"lon":113},{"facility":117,"status":38,"city":118,"state":119,"zip":120,"country":42,"cosmosGeoPoint":121,"geoPoint":125,"contacts":30},"UT MD Anderson Cancer Center","Houston","Texas","77030",{"type":44,"coordinates":122},[123,124],-95.36327,29.76328,{"lat":124,"lon":123},{"facility":127,"status":38,"city":128,"state":119,"zip":129,"country":42,"cosmosGeoPoint":130,"geoPoint":134,"contacts":30},"UT Health San Antonio Mays Cancer Center","San Antonio","78229",{"type":44,"coordinates":131},[132,133],-98.49363,29.42412,{"lat":133,"lon":132},{"facility":136,"status":38,"city":137,"state":138,"zip":139,"country":42,"cosmosGeoPoint":140,"geoPoint":144,"contacts":30},"Inova Center for Personalized Health","Fairfax","Virginia","22031",{"type":44,"coordinates":141},[142,143],-77.30637,38.84622,{"lat":143,"lon":142},{"facility":146,"status":38,"city":147,"state":148,"zip":149,"country":42,"cosmosGeoPoint":150,"geoPoint":154,"contacts":30},"UW Carbone Cancer Center","Madison","Wisconsin","53792",{"type":44,"coordinates":151},[152,153],-89.40123,43.07305,{"lat":153,"lon":152},{"type":156,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100054209",false,"NCT07428616","A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma","A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma","STELLAR-201","Key Inclusion Criteria:\n\n* Histologically confirmed World Health Organization (WHO) grade 1, 2, or 3 meningioma.\n* Developed recurrent disease or progressive disease (PD) after receiving standard therapy (for example, surgery and\u002For radiation) or have been deemed ineligible to receive these therapies. At least 1 prior course of meningioma-directed radiotherapy is required, if not contraindicated.\n* Radiologically documented progression of any existing tumor (growth \\> 15% of the bidimensional enhancing tumor within the prior 6 months or appearance of new lesions (including intra and extracranial manifestations).\n* For participants treated with external beam radiation, interstitial brachytherapy, or radiosurgery, an interval ≥ 24 weeks must have elapsed from completion of therapy to initiation of treatment.\n* Measurable disease by RANO meningioma criteria as determined by the investigator, obtained ≤ 14 days prior to initiation of treatment.\n* Karnofsky performance status (KPS) ≥ 60%.\n* Demonstrate adequate organ and marrow function within 14 days of treatment initiation\n\nKey Exclusion Criteria:\n\n* Prior history of hypertensive encephalopathy at any time.\n* Extracranial lesions invading major blood vessels including, but not limited to, inferior vena cava, pulmonary artery, or aorta.\n* Contraindication to magnetic resonance imaging (MRI).\n* Local therapy (surgery and\u002For radiation therapy) is indicated per investigator\n* Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks or 5 half-lives, whichever is shorter, before initiation of treatment. There is no limit on prior systemic therapies\n* Prior Surgery - completed wound healing must occur prior to initiation of treatment; ≥ 8 weeks for major surgery, ≥ 7 days for minor surgery, including stereotactic biopsies.\n* The participant has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n  * Cardiovascular disorders, including uncontrolled hypertension,\n  * Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation,\n  * Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 milliliters \\[mL\\]) of red blood within 12 weeks before initiation of treatment or other history of significant bleeding (eg, intracranial hemorrhage\u002Fbleeding), or\n  * Other clinically significant disorders.\n* Requirement for hemodialysis or peritoneal dialysis.\n* History of solid organ or allogeneic stem cell transplant.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":167,"type":168},100,"ESTIMATED","INTERVENTIONAL",[171],"PHASE2","The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.",[174],"Meningioma",[174,176,177,178,179,180,9,20,181,182,183,184,185],"Recurrent Meningioma","Progressive Meningioma","Atypical Meningioma","Anaplastic Meningioma","Brain","Grade 1 Meningioma","Grade 2 Meningioma","Grade 3 Meningioma","Intracranial Neoplasms","Extracranial Meningioma","2026-07-10",{"date":188,"type":189},"2026-07-13","ACTUAL",{"date":191,"type":189},"2026-05-21",{"date":193,"type":168},"2029-09-30",{"name":5,"class":6},12]